News | December 10, 2025
Lilly to invest $6 billion in Huntsville manufacturing hub
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Expands bioprocessing footprint across Asia
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The study met its primary endpoint and all 11 secondary efficacy endpoints
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Subscribe To Our Newsletter & Stay Updated
